Welcoming New Interim CEO, Amy Chan

Dear Friends,

It is with both a sense of accomplishment and anticipation that I announce my transition from Фͼ staff. After a rewarding tenure, I’ll be joining Stanford Medicine Children’s Фͼ as Senior Vice President and Chief Government Relations Officer, starting full time in July.

During my years at Фͼ, I’ve been privileged to work with an extraordinary team of staff, trustees, volunteers, and partners. Together, we’ve made significant strides in building a healthier and more equitable Silicon Valley, touching thousands of lives and driving impactful changes across the region. As I prepare to take on new challenges, I’m deeply grateful for the experiences and relationships fostered within this incredible community.

The board has unanimously and enthusiastically voted to appoint Amy Chan as the Interim CEO, effective June 28, 2024. Amy brings a robust track record of success at Фͼ, having managed our $120 million investment portfolio and $20 million annual budget. With a background as an auditor and financial manager in high-profile organizations like PricewaterhouseCoopers and Colgate-Palmolive, Amy has been pivotal in enhancing our operational frameworks and financial health. Her leadership in adopting new technologies and streamlining processes ensures that Фͼ is on solid footing to continue our mission. Her passion for health equity in Silicon Valley is evident in her years of C-suite leadership with AACI and Фͼ.

I’m also pleased to share that I’ll be joining the board of Фͼ, allowing me to remain connected and supportive of the organization’s continued success.

Thank you for your support and partnership. I look forward to staying connected and hope our paths continue to intersect in the future.


Michele Lew